Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LIF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
LIF is a gene implicated in neurodegeneration research. Key relationships include: activates, inhibits, therapeutic target. Associated with Autoimmune, Cancer, Carcinoma. Connected to 58 entities in the SciDEX knowledge graph.
| Gene Symbol | LIF |
| Full Name | Leukemia Inhibitory Factor |
| Aliases | Page for LIF Receptor Protein |
| Chromosome | 5p13.1 |
| Function | The LIF gene encodes a 202-amino acid secreted glycoprotein that acts as a multifunctional cytokine: |
| Molecular Weight | 190 kDa |
| Amino Acids | 202 aa |
| Exons | 20 |
| Pathways | MAPK, PI3K |
| UniProt ID | P15018 |
| NCBI Gene ID | 3977 |
| Ensembl ID | ENSG00000128342 |
| OMIM | 159446 |
| GeneCards | LIF |
| Human Protein Atlas | LIF |
| Associated Diseases | multiple sclerosis |
| Interactions | EGFR, STAT3, EP300, SMAD3, BRD4, BDNF |
| KG Connections | 128 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
LIF["<b>LIF</b>"]
LIFR["LIFR"]
LIF -->|"binds"| LIFR
neurite_damage(["neurite damage"])
LIF -->|"protects against"| neurite_damage
Cancer{"Cancer"}
LIF -->|"inhibits"| Cancer
Leukemia{"Leukemia"}
LIF -->|"inhibits"| Leukemia
Ms{"Ms"}
LIF -->|"activates"| Ms
Tumor{"Tumor"}
LIF -->|"activates"| Tumor
LIF -->|"activates"| Leukemia
Carcinoma{"Carcinoma"}
LIF -->|"activates"| Carcinoma
LIF -->|"activates"| Cancer
LIF -->|"therapeutic target"| Tumor
EGFR["EGFR"]
LIF -->|"activates"| EGFR
Epigenetic(["Epigenetic"])
LIF -->|"inhibits"| Epigenetic
JAK_STAT(["JAK-STAT"])
JAK_STAT -->|"activates"| LIF
EGFR -->|"activates"| LIF
GENES["GENES"]
GENES -->|"activates"| LIF
DNA["DNA"]
DNA -->|"activates"| LIF
STAT3["STAT3"]
STAT3 -->|"activates"| LIF
LIFR -->|"expressed in"| LIF
GFAP["GFAP"]
GFAP -->|"expressed in"| LIF
SOX2["SOX2"]
SOX2 -->|"activates"| LIF
LIFR -->|"activates"| LIF
AND["AND"]
AND -->|"inhibits"| LIF
CANCER["CANCER"]
CANCER -->|"inhibits"| LIF
HIPPO["HIPPO"]
HIPPO -->|"activates"| LIF
style LIF fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| Tumor | activates | disease | 0.75 |
| Leukemia | activates | disease | 0.75 |
| Cancer | activates | disease | 0.75 |
| neurite damage | protects_against | process | 0.70 |
| CANCER | activates | gene | 0.70 |
| CYTOKINES | inhibits | gene | 0.70 |
| Cancer | inhibits | disease | 0.65 |
| Leukemia | inhibits | disease | 0.65 |
| Ms | activates | disease | 0.65 |
| Carcinoma | activates | disease | 0.65 |
| Tumor | therapeutic_target | disease | 0.65 |
| Prostate Cancer | activates | disease | 0.65 |
| Autoimmune | therapeutic_target | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Infection | therapeutic_target | disease | 0.65 |
| Inflammation | therapeutic_target | disease | 0.65 |
| Multiple Sclerosis | activates | disease | 0.65 |
| ALS | expressed_in | disease | 0.65 |
| EGFR | activates | gene | 0.60 |
| LIFR | expressed_in | gene | 0.60 |
| STAT3 | activates | gene | 0.60 |
| EP300 | activates | gene | 0.60 |
| SMAD3 | activates | gene | 0.60 |
| BRD4 | activates | gene | 0.60 |
| GFAP | expressed_in | gene | 0.60 |
| BDNF | activates | gene | 0.60 |
| LIFR | activates | gene | 0.60 |
| CNTF | inhibits | gene | 0.60 |
| TNF | activates | entity | 0.60 |
| GEM | activates | gene | 0.60 |
| CAV1 | inhibits | gene | 0.60 |
| Radial Glia | activates | cell_type | 0.60 |
| HDAC5 | expressed_in | gene | 0.60 |
| TNF | expressed_in | gene | 0.60 |
| cancer | inhibits | disease | 0.60 |
| Epigenetic | inhibits | pathway | 0.60 |
| Hedgehog | activates | pathway | 0.60 |
| Tgf-Β | activates | pathway | 0.60 |
| Wnt | activates | pathway | 0.60 |
| Egfr Signaling | activates | pathway | 0.60 |
| Hippo Pathway | activates | pathway | 0.60 |
| Epigenetic | activates | pathway | 0.60 |
| CANCER | inhibits | gene | 0.60 |
| HIPPO | activates | gene | 0.60 |
| IL-6 | inhibits | gene | 0.60 |
| JAK | activates | gene | 0.60 |
| Tumor Microenvironment | activates | pathway | 0.60 |
| Differentiation | activates | pathway | 0.60 |
| Immune Checkpoint | activates | pathway | 0.60 |
| IL-6 | therapeutic_target | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| JAK-STAT | activates | pathway | 0.70 |
| EGFR | activates | gene | 0.60 |
| STAT3 | activates | gene | 0.60 |
| LIFR | expressed_in | gene | 0.60 |
| GFAP | expressed_in | gene | 0.60 |
| SOX2 | activates | gene | 0.60 |
| LIFR | activates | gene | 0.60 |
| CNTF | inhibits | gene | 0.60 |
| TNF | activates | gene | 0.60 |
| GEM | activates | gene | 0.60 |
| CAV1 | inhibits | gene | 0.60 |
| UBIQUITIN | inhibits | gene | 0.60 |
| CAV1 | activates | gene | 0.60 |
| HDAC5 | activates | gene | 0.60 |
| GENES | activates | gene | 0.60 |
| DNA | activates | gene | 0.60 |
| CANCER | inhibits | gene | 0.60 |
| HIPPO | activates | gene | 0.60 |
| CYTOKINES | inhibits | gene | 0.60 |
| INFLAMMATION | therapeutic_target | gene | 0.60 |
| AND | therapeutic_target | gene | 0.60 |
| CANCER | therapeutic_target | gene | 0.60 |
| JAK | activates | gene | 0.60 |
| WNT | activates | gene | 0.60 |
| IL-6 | inhibits | gene | 0.60 |
| HEDGEHOG | activates | gene | 0.60 |
| AND | inhibits | gene | 0.60 |
| ASTROCYTE | activates | gene | 0.60 |
| CYTOKINES | activates | gene | 0.60 |
| IL-17 | activates | gene | 0.60 |
| AND | activates | gene | 0.60 |
| ASTROCYTES | activates | gene | 0.60 |
| RNA | activates | gene | 0.60 |
| FGF | activates | gene | 0.60 |
| EGFR | co_expressed_with | gene | 0.50 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
developmental neurobiology | 2026-04-07 | 0 hypotheses
neurodegeneration | 2026-04-01 | 0 hypotheses
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegene [PMID:41900887] | Chen TY, Wu N, Sun X | Life (Basel) | 2026 | 1 |
| Allosteric properties of mammalian ALOX15 orthologs. [PMID:41654134] | Yang J, Borchert A, Kuhn H | J Biol Chem | 2026 | 1 |
| Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration, Proteost [PMID:40868276] | Voicu V, Toader C, Șerban M, Covache-Bus | Biomedicines | 2025 | 1 |
| Heat Shock Protein Family A Member 1A Attenuates Apoptosis and Oxidative Stress [PMID:40066224] | Liu H, Zhou Y, Wang Z, Liu D, Li Y, Lai | MedComm (2020) | 2025 | 1 |
| Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] | Han QQ, Shen SY, Liang LF, Chen XR, Yu J | Brain Behav Immun | 2024 | 1 |
| From sleep to cancer to neurodegenerative disease: the crucial role of Hsp70 in [PMID:37643058] | Ghosh S, Vashisth K, Ghosh S, Han SS, Bh | J Biomol Struct Dyn | 2024 | 1 |
| SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxid [PMID:38516826] | He G, Zhang Y, Feng Y, Chen T, Liu M, Ze | J Cell Mol Med | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Plasma proteins and onset of type 2 diabetes and diabetic complications: Proteom [PMID:37652020] | Yuan S, Xu F, Li X, Chen J, Zheng J, Man | Cell Rep Med | 2023 | 1 |
| Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via [PMID:37465997] | Chen X, He X, Xu F, Xu N, Sharifi NH, Zh | Stroke | 2023 | 1 |
| Microglia regulation of synaptic plasticity and learning and memory. [PMID:34472455] | Cornell J, Salinas S, Huang HY, Zhou M | Neural Regen Res | 2022 | 1 |
| Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Ca [PMID:35642214] | Wang M, Pan W, Xu Y, Zhang J, Wan J, Jia | J Inflamm Res | 2022 | 1 |
| CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. [PMID:34492237] | Subbarayan MS, Joly-Amado A, Bickford PC | Pharmacol Ther | 2022 | 1 |
| ALOX12 is required for p53-mediated tumour suppression through a distinct ferrop [PMID:30962574] | Chu B, Kon N, Chen D, Li T, Liu T, Jiang | Nat Cell Biol | 2019 | 1 |
| Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies. [PMID:30472260] | Singh NK, Rao GN | Prog Lipid Res | 2019 | 1 |
| An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-rep [PMID:29227475] | Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang | Nat Med | 2018 | 1 |
| Microglia in neurodegeneration. [PMID:30258234] | Hickman S, Izzy S, Sen P, Morsett L, El | Nat Neurosci | 2018 | 1 |
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. [PMID:27033548] | Hong S, Beja-Glasser VF, Nfonoyim BM, Fr | Science | 2016 | 1 |
| How neuroinflammation contributes to neurodegeneration. [PMID:27540165] | Ransohoff RM | Science | 2016 | 1 |
| Circulating heat shock protein 70 (HSPA1A) in normal and pathological pregnancie [PMID:19821156] | Molvarec A, Tamási L, Losonczy G, Madách | Cell Stress Chaperones | 2010 | 1 |